HHS Draws New Lines for Peptide Compounding: What Changes for 503A Pharmacies
On Oct. 30, 2026, HHS published an Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances that provides an interim pathway for…
DO
By Daniel Okafor · Regulatory Correspondent
Nov 9 19:43 ETSource: The National Law Review
From the source
Read at natlawreview.comHHS Draws New Lines for Peptide Compounding: What Changes for 503A Pharmacies
On Oct. 30, 2026, HHS published an Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances that provides an interim pathway for compounding drugs using six peptide bulk drug substances — BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500 — when specified conditions are met.
